Over the course of the previous three years, Galenika has undergone an intensive period of investment and transformation, thanks to which it has repositioned itself and took a solid second place on Serbia’s pharmaceutical market
We see great potential for further growth, both in the region and the EU markets, and one of the milestones last year was the establishment of Galenika International in Hungary, as our EU hub – says Galenika’s Milorad Ilić.
Compared to the customary practice of making acquisitions as a means of penetrating new markets in the pharmaceutical industry, it is definitely a more challenging option to build from scratch and believe in your brand when leveraging your investment. However, the set-up is particularly eased when entering EU markets.
Structuring operations in the EU, including consideration of the preferred corporate structure in the most appropriate EU country, is one of the most important decisions a company can make.
We have already registered 19 products, while the registration of another eight is underway
Incorporating a company is relatively straightforward, with several steps in which you can perform almost all activities online. The EU’s strict but predictable regulation enables you to carefully plan your activities and count the initial assumptions and timelines.
Over the course of the previous three years Galenika has undergone an intensive period of investment and transformation, thanks to which it has repositioned itself and took a solid second place in Serbia’s pharmaceutical market. Considering the fact that we see great potential for further growth, both in the region and in the EU markets, one of the milestones last year was the establishment of Galenika International in Hungary, as our EU hub. We have already registered 19 products, while the registration of another eight is underway.
As a modern and stable company with a great team and an innovative way of thinking, Galenika will become even bigger and develop a strong EU presence.